ECSP066397A - Forma farmacéutica sólida de posología - Google Patents

Forma farmacéutica sólida de posología

Info

Publication number
ECSP066397A
ECSP066397A EC2006006397A ECSP066397A ECSP066397A EC SP066397 A ECSP066397 A EC SP066397A EC 2006006397 A EC2006006397 A EC 2006006397A EC SP066397 A ECSP066397 A EC SP066397A EC SP066397 A ECSP066397 A EC SP066397A
Authority
EC
Ecuador
Prior art keywords
solid pharmaceutical
posology
pharmaceutical form
pharmaceutically acceptable
dosage form
Prior art date
Application number
EC2006006397A
Other languages
English (en)
Inventor
Joerg Rosenberg
Ulrich Reinhold
Bernd Liepold
Gunther Derndl
Jorg Breitenbach
Laman Alani
Soumojeet Ghosh
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34217089&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066397(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of ECSP066397A publication Critical patent/ECSP066397A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una forma farmacéutica sólida de posología que provee una mejorada biodisponibilidad oral, es presentada para los inhibidores de HIV proteasa. En particular, la forma de posología consiste en una dispersión sólida de al menos un inhibidor de proteasa HIV y al menos un polímero soluble en agua farmacéuticamente aceptable, y al menos un surfactante farmacéuticamente aceptable, el mencionado polímero soluble en agua con un Tg de al menos alrededor de 50º C., preferiblemente, el surfactante farmacéuticamente aceptable con un valor de HLB de alrededor de 4 a 10.
EC2006006397A 2003-08-28 2006-02-24 Forma farmacéutica sólida de posología ECSP066397A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/650,178 US20050048112A1 (en) 2003-08-28 2003-08-28 Solid pharmaceutical dosage form
EP2004027401 2004-08-23

Publications (1)

Publication Number Publication Date
ECSP066397A true ECSP066397A (es) 2006-08-30

Family

ID=34217089

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006397A ECSP066397A (es) 2003-08-28 2006-02-24 Forma farmacéutica sólida de posología

Country Status (31)

Country Link
US (1) US20050048112A1 (es)
EP (6) EP3354261A1 (es)
JP (6) JP4815348B2 (es)
KR (5) KR101563222B1 (es)
CN (5) CN1901884B (es)
AT (1) ATE516017T1 (es)
AU (3) AU2004283087C1 (es)
CA (2) CA2689639C (es)
CR (3) CR8256A (es)
CY (5) CY1111981T1 (es)
DK (5) DK1663183T3 (es)
EA (4) EA033224B1 (es)
EC (1) ECSP066397A (es)
ES (5) ES2399810T3 (es)
HK (1) HK1257502A1 (es)
HR (1) HRP20110555T1 (es)
HU (3) HUE035985T2 (es)
IL (3) IL173939A (es)
ME (2) MEP17608A (es)
MX (2) MXPA06002346A (es)
NO (3) NO330282B1 (es)
NZ (2) NZ545499A (es)
PL (5) PL2258346T3 (es)
PT (5) PT2258345T (es)
RS (2) RS59969B1 (es)
SG (3) SG145690A1 (es)
SI (5) SI2942051T1 (es)
TW (1) TWI342221B (es)
UA (1) UA85564C2 (es)
WO (1) WO2005039551A2 (es)
ZA (3) ZA200801362B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1175205B1 (en) * 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
AU2012202831B2 (en) * 2005-02-23 2015-01-22 Abbvie Inc. A solid pharmaceutical dosage formulation
KR20070025070A (ko) * 2005-08-31 2007-03-08 주식회사 대웅제약 시부트라민 및 계면활성제를 함유하는 고체분산체 및 그의제조방법
PT1962808E (pt) * 2005-12-14 2010-10-29 Hoffmann La Roche Formulação de precursor de fármaco para o hcv
RU2008128424A (ru) * 2005-12-14 2010-01-20 Сипла Лимитед (In) Фармацевтическая комбинация, включающая нуклеотидный и нуклеозидный ингибиторы обратной транскриптазы (такие как тенофовир и ламивудин) в различных частях дозы
WO2007087188A2 (en) * 2006-01-20 2007-08-02 Merck & Co., Inc. Taste-masked tablets and granules
EP1832281A1 (en) * 2006-03-10 2007-09-12 Abbott GmbH & Co. KG Process for producing a solid dispersion of an active ingredient
EP1880715A1 (en) 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
BRPI0714265A2 (pt) * 2006-08-10 2013-04-16 Cipla Ltd composiÇço oral sàlida, processo para preparar uma composiÇço oral sàlida, uso de uma composiÇço e mÉtodo para tratar hiv
CA2669938C (en) * 2006-11-15 2016-01-05 Abbott Laboratories Solid pharmaceutical dosage formulations
MX2009008935A (es) 2007-02-23 2009-11-02 Gilead Sciences Inc Moduladores de las propiedades farmacocineticas de productos terapeuticos.
GT200800303A (es) * 2007-12-24 2009-09-18 Combinacion anti-retroviral
ES2607814T3 (es) * 2008-02-28 2017-04-04 Abbvie Inc. Preparación de tabletas
WO2009153654A1 (en) * 2008-06-17 2009-12-23 Aurobindo Pharma Limited Solid dosage forms of antiretrovirals
CA2737400C (en) * 2008-10-07 2016-11-22 Astrazeneca Uk Limited Pharmaceutical formulation 514
US20120121722A1 (en) 2008-12-18 2012-05-17 Anup Avijit Choudhury Atazanavir formulations
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
TWI471321B (zh) 2009-06-08 2015-02-01 亞培公司 Ｂｃｌ－２族群抑制劑之口服醫藥劑型
WO2011013110A1 (en) 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Unit dosage forms of hiv protease inhibitors
US20110034489A1 (en) 2009-07-31 2011-02-10 Ranbaxy Laboratories Limited Solid dosage forms of hiv protease inhibitors
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CA2829186A1 (en) * 2011-03-07 2012-09-13 Bandi Parthasaradhi Reddy Amorphous form of lopinavir and ritonavir mixture
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
CA2837266A1 (en) 2011-05-27 2012-12-06 Hetero Research Foundation Amorphous ritonavir co-precipitated
JP2014521745A (ja) * 2011-08-16 2014-08-28 メルク・シャープ・アンド・ドーム・コーポレーション 安定した非晶質分散体を調製するための無機マトリックスと有機ポリマーの組み合わせの使用
EP2564832A1 (en) 2011-08-29 2013-03-06 Hexal AG Solid dosage form of HIV protease inhibitors
KR101794032B1 (ko) * 2011-09-21 2017-11-07 (주)바이오시네틱스 나노입자 제조방법
ES2587559T3 (es) 2012-03-07 2016-10-25 Ratiopharm Gmbh Forma farmacéutica que comprende lopinavir y ritonavir
HUE027829T2 (en) * 2012-03-07 2016-11-28 Ratiopharm Gmbh Dosage forms containing non-crystalline lopinavir and crystalline ritonavir
CN103655571B (zh) * 2012-09-11 2016-04-20 上海星泰医药科技有限公司 一种洛匹那韦和利托那韦复方高均匀度纳米共分散体及其制备方法
US9789063B2 (en) 2012-09-27 2017-10-17 Basf Se Storage-stable dust-free homogeneous particulate formulation
US9744240B2 (en) 2012-09-27 2017-08-29 Basf Se Storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin E-derivative and at least one hydrophilic polymer
EP2900219B1 (en) 2012-09-27 2016-07-06 Basf Se A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer
CN104684545B (zh) 2012-09-27 2018-04-03 巴斯夫欧洲公司 包含至少一种水溶性维生素e衍生物和至少一种亲水聚合物的储存稳定的无粉尘均质颗粒状配制剂
RU2505286C1 (ru) * 2012-12-29 2014-01-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
RU2543322C1 (ru) * 2013-09-19 2015-02-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
RU2619840C1 (ru) * 2016-09-21 2017-05-18 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция для лечения ВИЧ-инфекции
RU2659693C1 (ru) * 2017-06-30 2018-07-03 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции
US20190038754A1 (en) * 2017-08-07 2019-02-07 SE Tylose, USA, Inc. Pharmaceutical composition in solid extruded form
EP3758683A1 (en) * 2018-03-02 2021-01-06 The University Of Liverpool Solid compositions of actives, processes for preparing same and uses of such solid compositions
CN108186578A (zh) * 2018-03-27 2018-06-22 聊城大学 一种利托那韦固体分散体的制备方法
EP3569225A1 (en) 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Solid dispersion containing ritonavir
TWI799599B (zh) * 2019-06-06 2023-04-21 華納國際生物科技股份有限公司 醫藥或保健品自乳化固體分散組成物
CN114146061B (zh) * 2020-09-07 2023-06-30 歌礼生物科技（杭州）有限公司 包含固体分散体的蛋白酶抑制剂增效组合物及其制备方法
CA3203975A1 (en) 2020-12-03 2022-06-09 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
CA3216359A1 (en) 2021-04-07 2022-10-13 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
CN113318076B (zh) * 2021-06-02 2022-09-23 聊城大学 一种兼具增溶及抑晶效果的利托那韦固体分散体及其制备方法
CN114557967B (zh) * 2022-03-17 2023-06-02 乐普制药科技有限公司 一种利托那韦固体分散体的制备方法
AU2024353375A1 (en) 2023-09-29 2026-04-09 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2525108B1 (fr) 1982-04-19 1989-05-12 Elan Corp Ltd Medicaments a haut degre de solubilite et procede pour leur obtention
DE3830353A1 (de) 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
US5542206A (en) 1994-10-11 1996-08-06 Lisch; Albert Lure and tackle stacking container
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US6027747A (en) * 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
DE19841244A1 (de) * 1998-09-09 2000-03-16 Knoll Ag Verfahren und Vorrichtung zum Herstellen von Tabletten
ATE400252T1 (de) 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
DE19913606A1 (de) 1999-03-25 2000-09-28 Basf Ag Pulverförmige Solubilisationshilfsstoffe für feste pharmazeutische Darreichungsformen
DE19913692A1 (de) * 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
TR200103488T2 (tr) 1999-06-04 2002-04-22 Abbott Laboratories Geliştirilmiş farmasötik formülasyonlar.
CA2390092C (en) 1999-11-12 2009-07-14 Abbott Laboratories Solid dispersion pharmaceutical formulations
EP1175205B1 (en) * 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
BR0210520A (pt) 2001-06-22 2004-06-22 Pfizer Prod Inc Composições farmacêuticas de dispersões de fármacos amorfos misturados com polìmeros
DE60320940D1 (de) * 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
DE10213242A1 (de) * 2002-03-25 2003-10-16 Abbott Gmbh & Co Kg Testsystem zur Evaluierung der Kompatibilität biologisch aktiver Substanzen mit Copolymeren
DE10247037A1 (de) * 2002-10-09 2004-04-22 Abbott Gmbh & Co. Kg Herstellung von festen Dosierungsformen unter Verwendung eines vernetzten nichtthermoplastischen Trägers
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
CA2669938C (en) 2006-11-15 2016-01-05 Abbott Laboratories Solid pharmaceutical dosage formulations

Also Published As

Publication number Publication date
AU2004283087B2 (en) 2007-09-20
PL2942051T3 (pl) 2018-07-31
EP2258344A3 (en) 2011-01-19
KR101281994B1 (ko) 2013-07-04
CN102772380B (zh) 2015-08-19
RS20181262A1 (sr) 2019-02-28
HUE038792T2 (hu) 2018-11-28
EA200600473A1 (ru) 2006-10-27
CN1901884B (zh) 2012-07-25
DK2258346T3 (da) 2017-11-13
CN1901884A (zh) 2007-01-24
EP1663183A2 (en) 2006-06-07
ES2666390T3 (es) 2018-05-04
JP5395125B2 (ja) 2014-01-22
IL173939A0 (en) 2006-07-05
ZA200801362B (en) 2009-03-25
AU2010238573A1 (en) 2010-11-18
JP2016094433A (ja) 2016-05-26
PT1663183E (pt) 2011-08-25
EP2942051B1 (en) 2018-01-17
EP2258344A2 (en) 2010-12-08
DK2258345T3 (en) 2017-01-16
JP5498411B2 (ja) 2014-05-21
NZ545499A (en) 2009-11-27
KR20060121837A (ko) 2006-11-29
SG10201507902UA (en) 2015-10-29
EP2942051A1 (en) 2015-11-11
HK1257502A1 (en) 2019-10-25
EP1663183B9 (en) 2012-06-13
EP2258346A3 (en) 2011-01-19
AU2007249115B2 (en) 2010-08-12
CA2536638C (en) 2010-04-06
ZA200801361B (en) 2011-11-30
AU2007249115A1 (en) 2008-01-10
MEP17608A (en) 2010-06-10
SI2258344T1 (sl) 2013-03-29
PL1663183T3 (pl) 2011-10-31
JP2013241460A (ja) 2013-12-05
HK1217298A1 (en) 2017-01-06
EP3354261A1 (en) 2018-08-01
AU2004283087C1 (en) 2008-04-24
CR8256A (es) 2008-01-11
EP2258345B1 (en) 2016-09-21
KR101457967B1 (ko) 2014-11-07
CR20120662A (es) 2013-03-13
EA201890737A3 (ru) 2019-01-31
KR20140046078A (ko) 2014-04-17
NO20061342L (no) 2006-05-29
DK2258344T3 (da) 2013-01-02
KR101132602B1 (ko) 2012-04-06
NO20100367L (no) 2006-05-29
JP2011236232A (ja) 2011-11-24
SI2942051T1 (en) 2018-06-29
EA011924B1 (ru) 2009-06-30
ME00130B (me) 2010-10-10
ES2367173T3 (es) 2011-10-31
HUE035985T2 (hu) 2018-06-28
CN102772380A (zh) 2012-11-14
EP2258345A2 (en) 2010-12-08
KR101563222B1 (ko) 2015-10-26
PT2258346T (pt) 2017-10-24
PL2258344T3 (pl) 2013-04-30
SI2258346T1 (sl) 2017-12-29
UA85564C2 (ru) 2009-02-10
SG179401A1 (en) 2012-04-27
TWI342221B (en) 2011-05-21
PT2942051T (pt) 2018-04-23
RS59969B1 (sr) 2020-03-31
CA2689639A1 (en) 2005-05-06
JP4815348B2 (ja) 2011-11-16
PL2258345T3 (pl) 2017-03-31
KR20120054666A (ko) 2012-05-30
MX358033B (es) 2018-08-02
NO335326B1 (no) 2014-11-10
AU2004283087A1 (en) 2005-05-06
CN101919858B (zh) 2013-10-30
DK2942051T3 (en) 2018-05-07
RS20060140A (sr) 2008-09-29
EA020992B1 (ru) 2015-03-31
JP5903413B2 (ja) 2016-04-13
PT2258344E (pt) 2013-02-18
CA2689639C (en) 2014-06-10
CN102764244A (zh) 2012-11-07
EP2258346A2 (en) 2010-12-08
NO20131743L (no) 2006-05-29
CY1113596T1 (el) 2016-06-22
EA033224B1 (ru) 2019-09-30
EA200900292A1 (ru) 2009-06-30
EA201301045A1 (ru) 2014-05-30
JP2018035163A (ja) 2018-03-08
ATE516017T1 (de) 2011-07-15
WO2005039551A3 (en) 2006-08-03
CY1111981T1 (el) 2015-11-04
DK1663183T3 (da) 2011-08-29
ES2608720T3 (es) 2017-04-12
EP2258345A3 (en) 2011-01-19
HK1094766A1 (en) 2007-04-13
NO334418B1 (no) 2014-03-03
ZA200601718B (en) 2009-11-25
SI1663183T1 (sl) 2011-09-30
TW200522979A (en) 2005-07-16
KR20150044031A (ko) 2015-04-23
NZ579622A (en) 2011-01-28
JP2011126898A (ja) 2011-06-30
EA201890737A2 (ru) 2018-08-31
EP2258344B1 (en) 2012-11-14
KR20110122771A (ko) 2011-11-10
IL173939A (en) 2017-03-30
SG145690A1 (en) 2008-09-29
CY1118505T1 (el) 2017-07-12
MXPA06002346A (es) 2006-05-19
HUE031153T2 (en) 2017-07-28
AU2010238573B2 (en) 2012-12-13
HRP20110555T1 (hr) 2011-09-30
EP2258346B1 (en) 2017-09-27
CY1119651T1 (el) 2018-04-04
CR20120661A (es) 2013-03-13
US20050048112A1 (en) 2005-03-03
CN101919858A (zh) 2010-12-22
HK1145969A1 (en) 2011-05-13
SI2258345T1 (sl) 2017-01-31
IL207260A (en) 2017-10-31
PL2258346T3 (pl) 2018-01-31
CA2536638A1 (en) 2005-05-06
IL254581A0 (en) 2017-11-30
EP1663183B1 (en) 2011-07-13
WO2005039551A2 (en) 2005-05-06
RS57663B1 (sr) 2018-11-30
ES2399810T3 (es) 2013-04-03
PT2258345T (pt) 2017-01-20
CY1120138T1 (el) 2018-12-12
NO330282B1 (no) 2011-03-21
ES2653762T3 (es) 2018-02-08
JP2007504142A (ja) 2007-03-01
CN105106104A (zh) 2015-12-02

Similar Documents

Publication Publication Date Title
ECSP066397A (es) Forma farmacéutica sólida de posología
BRPI0413882A (pt) forma de dosagem farmacêutica sólida